Chester County News and Community Website
NEWTOWN SQUARE, PA — ArriVent BioPharma (Nasdaq: AVBP) received U.S. Food and Drug Administration clearance to begin human testing of an experimental antibody-drug conjugate designed to improve targeting of ovarian …
ArriVent Pushes Dual-Target Ovarian Cancer Drug Into Trials Read More
WILMINGTON, DE — NRx Pharmaceuticals (Nasdaq: NRXP) received U.S. Food and Drug Administration clearance to begin a late-stage clinical trial evaluating whether its investigational NRX-101 therapy can improve outcomes for …
NRx Advances Depression Drug Study Targeting Military Use Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) said it remains on track to submit a New Drug Application in the second half of 2026 for QTORIN rapamycin after reporting …
Palvella Eyes 2027 Launch After Positive Phase 3 Results Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) outlined plans for multiple mid- and late-stage clinical milestones this year as the biotechnology company advances experimental treatments for asthma, atopic dermatitis …
Aclaris Expands Immunology Pipeline Ahead of Key Trial Data Read More
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) expects interim clinical data from two experimental cancer therapies later this year as the biotechnology company advances multiple bispecific antibody programs targeting …
Context Therapeutics Advances Cancer Drug Pipeline Toward Data Readouts Read More
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) received a $15 million investment from Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) tied to the company’s ongoing cardiovascular device trials, completing …
Orchestra BioMed Secures Ligand Funding for Pivotal Trials Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) received a $20 million investment from Medtronic plc (NYSE: MDT) tied to the companies’ ongoing collaboration to develop a pacemaker-based …
Orchestra BioMed Secures Medtronic Funding for Hypertension Trial Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) reported additional Phase 2 trial data showing higher-dose treatment with its experimental SkinJect therapy produced stronger response rates in patients with nodular …
Medicus Pharma (Nasdaq: MDCX) Advances Lead Skin Cancer Regimen Read More
MALVERN, PA — Ocugen (NASDAQ: OCGN) reported positive mid-stage clinical data for its geographic atrophy gene therapy program while raising additional capital expected to fund operations into 2028 as the …
Ocugen Reports Positive GA Trial Data, Extends Cash Runway Read More WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) recently dosed the first patients in a Phase 2 study evaluating QTORIN rapamycin gel for angiokeratomas, a rare vascular-related skin disorder with no …
Palvella Doses First Patients in Rare Disease Skin Trial Read More